Company: PRGO
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001585364-25-000156
Chunk: 90

Company: PERRIGO Co plc
Filing Date: 2025-11-05
Form: 10-Q
Item: Part II, Item 1
Chunk 90
---
4 million decreased 2.6% due primarily to first half net lost distribution of lower margin products and lower category consumption of children's analgesics medicines and lower dollar share compared to prior year, partially offset by new business awards;

•Healthy Lifestyle: Net sales of $221.5 million increased 0.1% due primarily to new distribution and stronger base velocities, leading to market share gains in nicotine gums and lozenges, partially offset by lower category consumption;

•Oral Care: Net sales of $184.8 million decreased 9.8% due primarily to net lost distribution of lower margin products at specific retail customers and lower net sales of Plackers® dental flossers;

•Skin Care: Net sales of $165.2 million increased 4.2% due primarily to growth in the Mederma® brand and higher net sales in the Minoxidil franchise; 

•Women's Health: Net sales of $52.7 million decreased 14.9% due primarily to the prior year reflecting the strong initial retailer stocking of Opill®, which launched in March 2024, of $15.0 million, or an impact to the category of 24.2%; and

•VMS and Other: Net sales of $9.9 million decreased 35.7% due primarily to volume declines in the VMS category.

47

Perrigo Company plc - Item 2CSCA

Operating income increased $16.6 million, or 8.9%, due primarily to:

•$5.8 million increase in gross profit driven primarily by infant formula business recovery, benefits from our Supply Chain Reinvention Program and Project Energize, as well as lower materials inflation, partially offset by lower net sales volumes flow through primarily in U.S. OTC and unfavorable net pricing impacts. Gross profit as a percentage of net sales increased 120 basis points compared to the prior year due to the same factors that impacted gross profit.

•$10.8 million decrease in operating expenses driven by lower selling and administrative costs of $16.1 million due primarily to benefits from Project Energize and lower variable employee expenses, as well as decreased research and development expenses, partially offset by higher restructuring costs due primarily to Nutrition Network Optimization and Project Energize.

CONSUMER SELF-CARE INTERNATIONAL FINANCIAL RESULTS

Three Month Comparison

 Three Months Ended(in millions, except percentages)September 27, 2025September 28, 2024Net sales$397.7 $